What is the current stock price of Rein Therapeutics Inc. (RNTX)?

As of the latest market data, Rein Therapeutics Inc. (RNTX) is trading at $1.49. The stock has seen a loss of -2.61% today.

Does Rein Therapeutics Inc. (RNTX) pay a dividend?

Based on current data, Rein Therapeutics Inc. does not have a confirmed active dividend policy.

What is the market cap of Rein Therapeutics Inc.?

The current market capitalization of Rein Therapeutics Inc. (RNTX) is approximately unavailable.

RNTX

Rein Therapeutics Inc.·Healthcare

1.49

2.614%(−0.04)

Market Closed

1.68

12.752%(+0.19)

After Hours

Last Updated: — ET

52W L: $1.0252W H: $2.40

RNTX NEWS

defenseworld.net

Mar 14

Rein Therapeutics (NASDAQ:RNTX) Stock Price Up 1.6% – What’s Next?

Shares of Rein Therapeutics Inc. (NASDAQ: RNTX - Get Free Report) traded up 1.6% during trading on Friday. The stock traded as high as $1.3451 and last traded at $1.30. 44,298 shares changed hands during trading, a decline of 51% from the average session volume of 90,560 shares. The stock had previously closed at $1.28.

Company Profile

Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.

Sector

Healthcare

Industry

Medical - Pharmaceuticals

Employees

IPO Date

2017-06-29

Beta

1.40

Websitewww.reintx.com↗